

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Dingivan <i>et al.</i>	Confirmation No.:	3565
Serial No.:	10/657,006	Art Unit:	1644
Filed:	September 5, 2003	Examiner:	Skelding, Zachary S.
For:	METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTIBODIES (as amended)	Attorney Docket No.:	10271-116-999

AMENDMENT UNDER 37 C.F.R. §§ 1.111 AND 1.114

Commissioner for Patents
Electronic Filing

Sir:

In response to the final Office Action mailed February 22, 2008, and in accordance with the Rules of Practice, please consider the amendments and remarks made herein and enter them into the record for the application. Applicants submit herewith: (1) an Amendment Fee Transmittal with provision authorizing payment of the required fee; (2) a Petition for Extension of Time with a provision authorizing payment of the required fee; (3) a Request for Continued Examination with a provision authorizing payment of the required fee; (4) a Supplemental Information Disclosure Statement with a provision authorizing payment of any required fee; and (5) a revised PTO-1449 Form along with copies of references C237-C241 listed on the revised PTO-1449 Form.

It is believed that no additional fees are required in connection with this Amendment. However if the Patent Office determines otherwise, the Commissioner is hereby authorized to charge any required fee(s) to Jones Day Deposit Account 50-3013.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 6 of this paper.